| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $35.1M | +27.7% | +95.9% |
| SG&A Expense | $14.1M | +1159.4% | +9521.3% |
| Operating Income | -$49.2M | -4283.9% | — |
| Income Tax | $0 | — | — |
| Net Income | -$44.8M | -4973.8% | -2018.1% |
| EPS (Basic) | -$1.03 | +99.8% | +99.9% |
| EPS (Diluted) | -$1.03 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $408.7M | — | — |
| Short-term Investments | $59.5M | — | — |
| Current Assets | $476.0M | — | — |
| Total Assets | $484.8M | +145.6% | +152.1% |
| Current Liabilities | $35.7M | +1258.5% | — |
| Total Liabilities | $38.1M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$71.7M | — | — |
| Capital Expenditures | $533K | — | — |
| Investing Cash Flow | $65.6M | — | — |
| Financing Cash Flow | $384.0M | — | — |
| Free Cash Flow | -$72.2M | — | — |
| +99.9% |
| +367.5% |
| +574.6% |
| Stockholders' Equity | $446.7M | +6242.7% | — |